Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
NEW: Eli Lilly and Company's retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, met all primary and key secondary endpoints in the phase 3 TRIUMPH-4 trial in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity
During the establishment of reference intervals (RI), samples that exhibit any indicators of hemolysis, icterus, or lipemia, which could introduce interferences, are often excluded from the study to ensure the accuracy of the results
S., Robertson, E
Your weight loss goals matter too
Bismah Irfan, MD As of May 2026, retatrutide is not yet FDA-approved
US$ 26.41
US$ 29.30
US$ 27.47
US$ 27.63
US$ 21.61
US$ 21.95
US$ 26.59
